Fig. 1

The development of EGFR-TKIs. a Timeline of approval of all three generations of EGFR-TKIs in EGFR-mutated NSCLC. The chemical structures and the first approval time of EGFR-TKIs are presented. b The coverage of common EGFR mutations of four generations of EGFR-TKIs. EGFR mutations are comprised of single mutant, double mutant and triple mutant, which are targeted by corresponding EGFR-TKIs. FDA, US Food and Drug Administration; NMPA, China National Medical Products Administration; KFDA, Korea Food and Drug Administration